ERJ Open Research最新文献

{"title":"1-year health outcomes associated with systemic corticosteroids for COVID-19: a longitudinal cohort study.","authors":"Olivia C Leavy, Richard J Russell, Ewen M Harrison, Nazir I Lone, Steven Kerr, Annemarie B Docherty, Aziz Sheikh, Matthew Richardson, Omer Elneima, Neil J Greening, Victoria Claire Harris, Linzy Houchen-Wolloff, Hamish J C McAuley, Ruth M Saunders, Marco Sereno, Aarti Shikotra, Amisha Singapuri, Raminder Aul, Paul Beirne, Charlotte E Bolton, Jeremy S Brown, Gourab Choudhury, Nawar Diar Bakerly, Nicholas Easom, Carlos Echevarria, Jonathan Fuld, Nick Hart, John R Hurst, Mark Jones, Dhruv Parekh, Paul Pfeffer, Najib M Rahman, Sarah Rowland-Jones, Ajay M Shah, Dan G Wootton, Caroline Jolley, A A Roger Thompson, Trudie Chalder, Melanie J Davies, Anthony De Soyza, John R Geddes, William Greenhalf, Simon Heller, Luke Howard, Joseph Jacob, R Gisli Jenkins, Janet M Lord, Will D-C Man, Gerry P McCann, Stefan Neubauer, Peter J M Openshaw, Joanna Porter, Matthew J Rowland, Janet T Scott, Malcolm G Semple, Sally J Singh, David Thomas, Mark Toshner, Keir Lewis, Liam G Heaney, Andrew Briggs, Bang Zheng, Mathew Thorpe, Jennifer K Quint, James D Chalmers, Ling-Pei Ho, Alex Horsley, Michael Marks, Krisnah Poinasamy, Betty Raman, Louise V Wain, Christopher E Brightling, Rachael A Evans","doi":"10.1183/23120541.00474-2024","DOIUrl":"10.1183/23120541.00474-2024","url":null,"abstract":"<p><strong>Background: </strong>In patients with coronavirus disease 2019 (COVID-19) requiring supplemental oxygen, dexamethasone reduces acute severity and improves survival, but longer-term effects are unknown. We hypothesised that systemic corticosteroid administration during acute COVID-19 would be associated with improved health-related quality of life (HRQoL) 1 year after discharge.</p><p><strong>Methods: </strong>Adults admitted to hospital between February 2020 and March 2021 for COVID-19 and meeting current guideline recommendations for dexamethasone treatment were included using two prospective UK cohort studies (Post-hospitalisation COVID-19 and the International Severe Acute Respiratory and emerging Infection Consortium). HRQoL, assessed by the EuroQol-Five Dimensions-Five Levels utility index (EQ-5D-5L UI), pre-hospital and 1 year after discharge were compared between those receiving corticosteroids or not after propensity weighting for treatment. Secondary outcomes included patient-reported recovery, physical and mental health status, and measures of organ impairment. Sensitivity analyses were undertaken to account for survival and selection bias.</p><p><strong>Findings: </strong>Of the 1888 participants included in the primary analysis, 1149 received corticosteroids. There was no between-group difference in EQ-5D-5L UI at 1 year (mean difference 0.004, 95% CI -0.026-0.034). A similar reduction in EQ-5D-5L UI was seen at 1 year between corticosteroid exposed and nonexposed groups (mean±sd change -0.12±0.22 <i>versus</i> -0.11±0.22). Overall, there were no differences in secondary outcome measures. After sensitivity analyses modelled using a cohort of 109 318 patients admitted to hospital with COVID-19, EQ-5D-5L UI at 1 year remained similar between the two groups.</p><p><strong>Interpretation: </strong>Systemic corticosteroids for acute COVID-19 have no impact on the large reduction in HRQoL 1 year after hospital discharge. Treatments to address the persistent reduction in HRQoL are urgently needed.</p>","PeriodicalId":11739,"journal":{"name":"ERJ Open Research","volume":"10 5","pages":""},"PeriodicalIF":4.3,"publicationDate":"2024-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11440406/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142343945","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Associations between respiratory pathogens and lung function in primary ciliary dyskinesia: cross-sectional analysis from the PROVALF-PCD cohort.","authors":"Bruna Rubbo, Avni Kant, Kewei Zhang, Annalisa Allegorico, Simona Basilicata, Mieke Boon, Melissa Borrelli, Claudia Calogero, Siobhán B Carr, Mary Carroll, Carolina Constant, Silvia Castillo Corullón, Harriet Corvol, Renato Cutrera, Stefanie Dillenhöfer, Nagehan Emiralioglu, Ela Eralp, Sanem Eryilmaz Polat, Laura Gardner, Yasemin Gokdemir, Amanda Harris, Claire Hogg, Bulent Karadag, Helene Kobbernagel, Cordula Koerner-Rettberg, Panayiotis Kouis, Natalie Lorent, Markella Marcou, June K Mathin, Vendula Martinu, Antonio Moreno-Galdó, Lucy Morgan, Kim G Nielsen, Heymut Omran, Ugur Ozcelik, Petr Pohunek, Johanna Raidt, Phil Robinson, Sandra Rovira-Amigo, Francesca Santamaria, Anne Schlegtendal, Aline Tamalet, Guillaume Thouvenin, Nicola Ullmann, Woolf Walker, Panayiotis Yiallouros, Claudia E Kuehni, Philipp Latzin, Nicole Beydon, Jane S Lucas","doi":"10.1183/23120541.00253-2024","DOIUrl":"10.1183/23120541.00253-2024","url":null,"abstract":"<p><strong>Introduction: </strong>Respiratory pathogens are frequently isolated from airway samples in primary ciliary dyskinesia (PCD) patients. Few studies have investigated associations between these pathogens and lung function, with current management based on evidence from cystic fibrosis. We investigated the association between commonly isolated respiratory pathogens and lung function in PCD patients.</p><p><strong>Methods: </strong>Using a cross-sectional design, we prospectively collected clinical and concurrent microbiology data from 408 participants with probable or confirmed PCD, aged ≥5 years, from 12 countries. We used Global Lung Function Initiative 2012 references to calculate forced expiratory volume in 1 s (FEV₁) z-scores. For 351 patients (86%) with complete data, we assessed the association of the four most frequently isolated pathogens with lung function by fitting multilevel linear models with country as random intercept, adjusted for age at diagnosis, age at lung function, use of antibiotic prophylaxis and body mass index z-scores.</p><p><strong>Results: </strong>Individuals with <i>Pseudomonas aeruginosa</i> growth in culture had significantly lower FEV₁ z-scores (β= -0.87, 95% CI -1.40- -0.34), adjusted for presence of <i>Haemophilus influenzae</i>, methicillin-sensitive <i>Staphylococcus aureus</i> and <i>Streptococcus pneumoniae</i>, and for covariates. When stratified by age, associations remained strong for adults but not for children. Results were similar when ciliary defects by transmission electron microscopy were included in the models and when restricting analysis to only confirmed PCD cases.</p><p><strong>Conclusions: </strong>We found that <i>P. aeruginosa</i> was associated with worse lung function in individuals with PCD, particularly adults. These findings suggest that it is prudent to aim for <i>P. aeruginosa</i> eradication in the first instance, and to treat exacerbations promptly in colonised patients.</p>","PeriodicalId":11739,"journal":{"name":"ERJ Open Research","volume":"10 5","pages":""},"PeriodicalIF":4.3,"publicationDate":"2024-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11440376/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142336352","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Secondary spontaneous pneumothorax as the presenting manifestation of filamin A-associated lung disease.","authors":"Simon Holden, Allanah P Barker, Judith Babar, Sumit Karia, Nandita Gupta, Rudy Sinharay, Stefan J Marciniak","doi":"10.1183/23120541.00011-2024","DOIUrl":"10.1183/23120541.00011-2024","url":null,"abstract":"<p><p><b>Secondary pneumothorax due to early-onset emphysema can be a presenting feature of filamin A mutation.</b> https://bit.ly/3ycAeCs.</p>","PeriodicalId":11739,"journal":{"name":"ERJ Open Research","volume":"10 5","pages":""},"PeriodicalIF":4.3,"publicationDate":"2024-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11440369/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142343951","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The impact of cardiovascular events in bronchiectasis: a systematic review and meta-analysis.","authors":"Andrea Gramegna, Ivan Barone, Gianfranco Alicandro, Giovanni Sotgiu, Angela Bellofiore, Crizia Colombo, Antonella Arcadu, Margherita Ori, Federico Blasi, Edoardo Simonetta, Marco Vicenzi, Stefano Aliberti, Francesco Blasi","doi":"10.1183/23120541.01032-2023","DOIUrl":"10.1183/23120541.01032-2023","url":null,"abstract":"<p><strong>Background: </strong>Bronchiectasis is a chronic respiratory condition characterised by airway and systemic inflammation with prevalence increasing with age. Given the median age of the patients, it is common to observe the presence of comorbidities, particularly cardiovascular diseases, which have been linked to adverse clinical outcomes. To investigate the pooled estimates of the association between bronchiectasis and coronary heart disease or stroke within this population, we conducted a systematic review and meta-analysis of the available scientific evidence.</p><p><strong>Methods: </strong>Three investigators independently performed the search on PubMed and other sources and included studies published up to October 2023 according to predefined criteria. Relative measures of association between bronchiectasis and cardiovascular events were pooled and meta-analysed using a fixed-effects model. Studies were evaluated using the Newcastle-Ottawa Scale for assessing the quality of non-randomised studies in meta-analyses.</p><p><strong>Results: </strong>A final pool of nine studies was included in the systematic review, with a total of 22 239 patients. Meta-analysis of three high-quality cohort studies showed a pooled hazard ratio of 1.42 (95% CI 1.30-1.57) for coronary heart disease and 1.71 (95% CI 1.55-1.89) for cerebrovascular stroke.</p><p><strong>Conclusions: </strong>The increased cardiovascular risk among people with bronchiectasis underscores the critical need to raise awareness of this association and to develop preventive strategies accordingly. Further translational studies are imperative to gain a deeper understanding of the complex interplay between inflammation, the immune system and endothelial dysfunction in this patient group.</p>","PeriodicalId":11739,"journal":{"name":"ERJ Open Research","volume":"10 5","pages":""},"PeriodicalIF":4.3,"publicationDate":"2024-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11440384/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142343953","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Anti-inflammatory reliever therapy (AIR) for asthma.","authors":"Mark L Levy, Michael G Crooks","doi":"10.1183/23120541.00494-2024","DOIUrl":"10.1183/23120541.00494-2024","url":null,"abstract":"<p><p><b>SABA overuse is prevalent and dangerous in asthma. Use of anti-inflammatory relievers (ICS/formoterol) in asthma mitigates against risk associated with SABA overuse and poor ICS adherence, and is the preferred approach for asthma management.</b> https://bit.ly/4aHOLn8.</p>","PeriodicalId":11739,"journal":{"name":"ERJ Open Research","volume":"10 5","pages":""},"PeriodicalIF":4.3,"publicationDate":"2024-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11440371/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142343946","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Priorities and barriers for research related to primary ciliary dyskinesia.","authors":"Myrofora Goutaki, Yin Ting Lam, Bruna Rubbo, James D Chalmers, Panayiotis Kouis, Gemma Marsh, Jean-François Papon, Johanna Raidt, Phil Robinson, Laura Behan, Jane S Lucas","doi":"10.1183/23120541.00026-2024","DOIUrl":"10.1183/23120541.00026-2024","url":null,"abstract":"<p><strong>Background: </strong>Despite advances in primary ciliary dyskinesia (PCD) research, many questions remain; diagnosis is complex and no disease-specific therapies exist. Using a mixed-methods approach, we aimed to identify priorities for clinical and epidemiological research and explore barriers to research.</p><p><strong>Methods: </strong>To obtain rich, relevant, diverse data, we performed in-depth semi-structured interviews with PCD specialists selected using purposive sampling. We transcribed, coded and analysed interview data using thematic analysis. Based on interview themes that we identified, we developed an anonymous survey and circulated it widely through the BEAT-PCD network.</p><p><strong>Results: </strong>We interviewed 28 participants from 15 countries across different disciplines and expertise levels. The main themes identified as priorities for PCD research were improving diagnosis; understanding prevalence and disease course; phenotypic variability; disease monitoring; treatment strategies; clinical trial end-points; and poorly researched areas. In total, 136 participants (49% paediatric pulmonologists) from 36 countries completed the survey. Most commonly reported barriers for research were low awareness about PCD and difficulties securing funding - in more than one-third of cases, participants reported undertaking predominantly unfunded research. Research questions ranked highest included priorities related to further improving diagnosis, treating PCD, managing upper and lower airway problems, and studying clinical variability and disease prognosis.</p><p><strong>Conclusion: </strong>We need to overcome barriers of limited funding and low awareness and promote collaborations between centres, disciplines, experts and patients to address identified PCD priorities effectively. Our results contribute to the ongoing efforts of guiding the use of existing limited research resources and setting up a roadmap for future research activities.</p>","PeriodicalId":11739,"journal":{"name":"ERJ Open Research","volume":"10 5","pages":""},"PeriodicalIF":4.3,"publicationDate":"2024-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11440378/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142343949","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Symptoms of COPD in the absence of airflow obstruction are more indicative of pre-COPD than overdiagnosis.","authors":"Daniella A Spittle, Maximillian Thomas, Caitlin Stevens, Abdulrhman Gazwani, Sally Fenton, Joshua De Soyza, Alice M Turner","doi":"10.1183/23120541.00264-2024","DOIUrl":"10.1183/23120541.00264-2024","url":null,"abstract":"<p><strong>Background: </strong>Dysfunction of the small airways is a precursor of COPD but is not detectable on standard spirometric testing until significant destruction has occurred. A proportion of COPD patients have a forced expiratory volume in 1 s (FEV₁)/forced vital capacity (FVC) <0.7 which is greater than the lower limit of normal (LLN), when adjusted for their age and sex. It is not understood whether this group of patients, known as \"discordant COPD\", are representative of \"early COPD\" or overdiagnosis.</p><p><strong>Methods: </strong>We sought to characterise discordant COPD (disCOPD) using radiology, lung function, serum biomarkers, activity monitoring and quality-of-life scores, comparing with COPD patients with an FEV₁/FVC <0.7 and <LLN and healthy, age-matched controls.</p><p><strong>Results: </strong>Six out of eight serum biomarkers were significantly different in the disCOPD group <i>versus</i> healthy controls, as were the scores of all four quality-of-life questionnaires. Activity monitoring revealed similar levels of sedentary time between the disCOPD group and concordant COPD (conCOPD). Computed tomography analysis showed less involvement of small airway dysfunction and emphysema in the disCOPD group <i>versus</i> conCOPD.</p><p><strong>Conclusions: </strong>Collectively, our findings support the hypothesis that disCOPD is a clinically relevant phenomenon that represents a pre-COPD state. Identification of such patients is important for early intervention and management before progression to fully established COPD.</p>","PeriodicalId":11739,"journal":{"name":"ERJ Open Research","volume":"10 5","pages":""},"PeriodicalIF":4.3,"publicationDate":"2024-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11440379/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142343952","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Utility of microRNA analysis in exhaled breath condensate of sarcoidosis and mediastinal tuberculosis patients: a pilot study.","authors":"Bijay Pattnaik, Sryma Pb, Naveen Bhatraju, Saurabh Mittal, Sudheer Arava, Deepali Jain, Baibaswata Nayak, Pavan Tiwari, Vijay Hadda, Anant Mohan, Anurag Agrawal, Randeep Guleria, Karan Madan","doi":"10.1183/23120541.00078-2024","DOIUrl":"10.1183/23120541.00078-2024","url":null,"abstract":"<p><strong>Background: </strong>Sarcoidosis and tuberculosis (TB) are the two most common causes of granulomatous mediastinal lymphadenopathy. These often exhibit overlapping clinical and radiological characteristics, rendering accurate diagnosis difficult. MicroRNA (miRNA) analysis is increasingly utilised as a potential biomarker for various diseases. Exhaled breath condensate (EBC) is a noninvasive technique for biomarker evaluation in different respiratory conditions. We attempted to identify differentially expressed miRNAs in the EBC of sarcoidosis and mediastinal TB patients.</p><p><strong>Methods: </strong>EBC was obtained from subjects with a definitive diagnosis of sarcoidosis and mediastinal TB. EBC was also obtained from age- and sex-matched control subjects. From EBC, miRNA isolation, cDNA preparation and qPCR array were performed. Differentially expressed miRNAs were shortlisted. Further validation was conducted in the EBC of a new subset.</p><p><strong>Results: </strong>Subjects with a definitive diagnosis of sarcoidosis (50) and TB (50), and control subjects (50) were included. qPCR array from EBC (20 subjects from each group) shortlisted eight differentially expressed miRNAs (miR-126, miR-132, miR-139-3p, miR-139-5p, miR-181c, miR-454, miR-512-3p and miR-362-5p). In the validation set (EBC of 30 subjects from each group), miR-126 and miR-132 were differentially expressed significantly. The miR-126 and miR-132 expression ratio could differentiate sarcoidosis from mediastinal TB with an AUC of 0.618 (82% specificity and 41% sensitivity).</p><p><strong>Conclusion: </strong>While EBC miRNA expression is significantly and differently altered in sarcoidosis and mediastinal TB, a simple ratiometric approach failed to provide clinically useful signatures for differentiating between the two in patients with mediastinal lymphadenopathy.</p>","PeriodicalId":11739,"journal":{"name":"ERJ Open Research","volume":"10 5","pages":""},"PeriodicalIF":4.3,"publicationDate":"2024-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11440382/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142343954","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Post-pandemic seasonal dynamics of hospitalised COPD exacerbations and aetiologies in the COPD population.","authors":"Hnin Aung, Aye Aung, Hamish J C McAuley, Omer Elneima, Cara Flynn, Tracy Thornton, Helen Evans, Christopher E Brightling, Adam Wright, Neil J Greening","doi":"10.1183/23120541.00258-2024","DOIUrl":"10.1183/23120541.00258-2024","url":null,"abstract":"<p><p><b>This study uncovered a reversal of seasonal variation in hospitalised COPD exacerbation events after the COVID-19 pandemic. Investigation of updated seasonal exacerbation patterns and triggers can help initiate preventive strategies effectively.</b> https://bit.ly/3wN71h0.</p>","PeriodicalId":11739,"journal":{"name":"ERJ Open Research","volume":"10 5","pages":""},"PeriodicalIF":4.3,"publicationDate":"2024-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11440372/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142343948","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Objective measurement of cough in pulmonary fibrosis: a cohort study - ImpaCT.","authors":"Jad Kebbe, Simon P Hart, Robert J Kaner, Tejaswini Kulkarni, Lutz Wollin, Carl Coeck, Richard Vinisko, Nina Patel, Marlies S Wijsenbeek","doi":"10.1183/23120541.00310-2024","DOIUrl":"10.1183/23120541.00310-2024","url":null,"abstract":"<p><p><b>Using both objective cough monitoring and patient-reported outcomes measures, this study describes the burden of cough for patients with non-IPF pulmonary fibrosis</b> https://bit.ly/3wFm0th.</p>","PeriodicalId":11739,"journal":{"name":"ERJ Open Research","volume":"10 5","pages":""},"PeriodicalIF":4.3,"publicationDate":"2024-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11440380/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142336354","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}